The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER+, HER2- early breast cancer

British Journal of Cancer

Volumn 111, Issue 5, 2014, Pages 837-842

  Exner, R ^a   Bago Horvath, Z ^a   Bartsch, R ^a   Mittlboeck, M ^a   Retel V P ^b   Fitzal, F ^a   Rudas, M ^a   Singer, C ^c   Pfeiler, G ^c   Gnant, M ^a   Jakesz, R ^a   Dubsky, P ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

Author keywords

adjuvant systemic treatment; breast cancer; gene expression profiling; tumour board recommendation

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR;

ADULT; AGED; ARTICLE; BIOMEDICAL TECHNOLOGY ASSESSMENT; CANCER RISK; CLINICAL FEATURE; COST EFFECTIVENESS ANALYSIS; DNA MICROARRAY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; NEEDLE BIOPSY; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS;

BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RISK; TRANSCRIPTOME;

EID: 84906934415     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.339     Document Type: Article

References (23)

1. Albain KS, Paik S, Van't Veer L (2009) Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays. Breast 18(Suppl 3): S141-S145.
2. Azim HA Jr, Michiels S, Zagouri F, Delaloge S, Filipits M, Namer M, Neven P, Symmans WF, Thompson A, Andre F, Loi S, Swanton C (2013) Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement. Ann Oncol 24: 647-654.
3. Bago-Horvath Z, Rudas M, Dubsky P, Jakesz R, Singer CF, Kemmerling R, Greil R, Jelen A, Bohm G, Jasarevic Z, Haid A, Gruber C, Postlberger S, Filipits M, Gnant M (2011) Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer. Clin Cancer Res 17: 7828-7834.
4. Bueno-De-Mesquita JM, Linn SC, Keijzer R, Wesseling J, Nuyten DS, Van Krimpen C, Meijers C, De Graaf PW, Bos MM, Hart AA, Rutgers EJ, Peterse JL, Halfwerk H, De Groot R, Pronk A, Floore AN, Glas AM, Van't Veer LJ, Van De Vijver MJ (2009) Validation of 70-gene prognosis signature in node-negative breast cancer. Breast Cancer Res Treat 117: 483-495.
5. Buyse M, Loi S, Van't Veer L, Viale G, Delorenzi M, Glas AM, D'assignies MS, Bergh J, Lidereau R, Ellis P, Harris A, Bogaerts J, Therasse P, Floore A, Amakrane M, Piette F, Rutgers E, Sotiriou C, Cardoso F, Piccart MJ (2006) Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 98: 1183-1192.
6. Drukker CA, Bueno-De-Mesquita JM, Retel VP, Van Harten WH, Van Tinteren H, Wesseling J, Roumen RM, Knauer M, Van 'T Veer LJ, Sonke GS, Rutgers EJ, Van De Vijver MJ, Linn SC (2013) A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. Int J Cancer 133: 929-936.
7. Dubsky PC, Jakesz R, Mlineritsch B, Postlberger S, Samonigg H, Kwasny W, Tausch C, Stoger H, Haider K, Fitzal F, Singer CF, Stierer M, Sevelda P, Luschin-Ebengreuth G, Taucher S, Rudas M, Bartsch R, Steger GG, Greil R, Filipcic L, Gnant M (2012) Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 30: 722-728.
8. Glas AM, Floore A, Delahaye LJ, Witteveen AT, Pover RC, Bakx N, Lahti-Domenici JS, Bruinsma TJ, Warmoes MO, Bernards R, Wessels LF, Van't Veer LJ (2006) Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics 7: 278.
9. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Postlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Rucklinger E, Greil R, Marth C (2009) Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360: 679-691.
10. Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Heck D, Menzel C, Jakesz R, Seifert M, Hubalek M, Pristauz G, Bauernhofer T, Eidtmann H, Eiermann W, Steger G, Kwasny W, Dubsky P, Hochreiner G, Forsthuber EP, Fesl C, Greil R (2011) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 12: 631-641.
11. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ (2009) Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 20: 1319-1329.
12. Jakesz R, Hausmaninger H, Kubista E, Gnant M, Menzel C, Bauernhofer T, Seifert M, Haider K, Mlineritsch B, Steindorfer P, Kwasny W, Fridrik M, Steger G, Wette V, Samonigg H (2002) Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer-Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol 20: 4621-4627.
13. Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W, Menzel C, Samonigg H, Seifert M, Gademann G, Kaufmann M, Wolfgang J (2005) Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366: 455-462.
14. Mook S, Schmidt MK, Weigelt B, Kreike B, Eekhout I, Van De Vijver MJ, Glas AM, Floore A, Rutgers EJ, Van 'T Veer LJ (2010) The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. Ann Oncol 21: 717-722.
15. Reiner A, Neumeister B, Spona J, Reiner G, Schemper M, Jakesz R (1990) Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer. Cancer Res 50: 7057-7061.
16. Retel VP, Joore MA, Drukker CA, Bueno-De-Mesquita JM, Knauer M, Van Tinteren H, Linn SC, Van Harten WH (2013) Prospective costeffectiveness analysis of genomic profiling in breast cancer. Eur J Cancer 49: 3773-3779.
17. Retel VP, Joore MA, Knauer M, Linn SC, Hauptmann M, Harten WH (2010) Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer. Eur J Cancer 46: 1382-1391.
18. Rouzier R, Pronzato P, Chéreau E, Carlson J, Hunt B, Valentine WJ (2013) Multigene assays and molecular markers in breast cancer: systematic review of health economic. Breast Cancer Res Treat 139: 621-637.
19. Rutgers E, Piccart-Gebhart MJ, Bogaerts J, Delaloge S, Veer LV, Rubio IT, Viale G, Thompson AM, Passalacqua R, Nitz U, Vindevoghel A, Pierga JY, Ravdin PM, Werutsky G, Cardoso F (2011) The EORTC 10041/BIG 03-04 MINDACT trial is feasible: results of the pilot phase. Eur J Cancer 47: 2742-2749.
20. Sapino A, Roepman P, Linn SC, Snel MH, Delahaye LJ, Van Den Akker J, Glas AM, Simon IM, Barth N, De Snoo FA, Van 'T Veer LJ, Molinaro L, Berns EM, Wesseling J, Riley LB, Anderson D, Nguyen B, Cox CE (2013) MammaPrint molecular diagnostics on formalin-fixed, paraffin-embedded tissue. J Mol Diagn 16(2): 190-197.
21. Van't Veer LJ, Dai H, Van De Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, Van Der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536.
22. Van De Vijver MJ, He YD, Van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, Van Der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R (2002) A geneexpression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009.
23. Yang M, Rajan S, Issa AM (2012) Cost effectiveness of gene expression profiling for early stage breast cancer: a decision-analytic model. Cancer 118: 5163-5170.